Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy

Lei Qiu; Feng Zhu; Guoqing Wei; Wenjun Wu; Luxin Yang; Yongxian Hu; He Huang

doi:10.1016/j.reth.2020.03.005

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy

Regen Ther. 2020 May 15:14:271-274. doi: 10.1016/j.reth.2020.03.005. eCollection 2020 Jun.

Authors

Lei Qiu^{1

2}, Feng Zhu^{1

2}, Guoqing Wei^{2

3

4}, Wenjun Wu^{2

3

4}, Luxin Yang^{2

3

4}, Yongxian Hu^{2

3

4}, He Huang^{2

3

4}

Affiliations

¹ Department of Hematology, Zhoushan Hospital, Zhoushan, 310000, China.
² Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
³ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 310000, China.
⁴ Institute of Hematology, Zhejiang University, Hangzhou, 310000, China.

Abstract

The adoptive transfer of CAR-T cells, which are modified T cells expressing chimeric antigen receptors (CARs), to target B cell maturation antigen (BCMA) has demonstrated impressive results in treating relapsed/refractory multiple myeloma. Although BCMA CAR-T therapy induces certain complications in some patients, idiopathic thrombocytopenic purpura (ITP) has not been reported as one of them. To the best of our knowledge, this is the first report of the successful treatment of ITP that arose in a relapsed/refractory multiple myeloma patient following anti-BCMA CAR-T cell infusion. Herein, we describe this relatively uncommon complication and provide guidance on its treatment.

Keywords: B cell maturation antigen; BCMA CAR-T therapy; BCMA, B cell maturation antigen; CAR-Ts, chimeric antigen receptor T cells; CARS, chimeric antigen receptors; CR, complete remission; CRS, cytokine release syndrome; Chimeric antigen receptor T cells; ITP, idiopathic thrombocytopenic purpura; Idiopathic thrombocytopenic purpura; Relapsed/refractory multiple myeloma.